KemPharm is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs.

We employ our Ligand Activated Therapy (LAT™) platform technology to create new molecular entity (NME) prodrugs in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create NME prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect.

KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.

KemPharm’s co-lead clinical development candidates are KP415, an extended-release (ER) prodrug of methylphenidate (MPH) for the treatment of attention deficit hyperactivity disorder (ADHD), and KP201/IR, an acetaminophen (APAP)-free formulation of our immediate release (IR) abuse deterrent hydrocodone product, KP201. In addition, KemPharm is rapidly advancing the development of KP484, a super-extended release (SER) methlyphenidate prodrug for the treatment of ADHD, while continuing its development of KP511, an NME prodrug of hydromorphone designed to be abuse-deterrent.  KemPharm is developing KP511 in both extended release (ER) and immediate release (IR) formulations.